Development of an
18F-fluoride
CD8
ImmunoPET
VHH
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
20
05
2022
accepted:
09
10
2022
pubmed:
9
11
2022
medline:
24
1
2023
entrez:
8
11
2022
Statut:
ppublish
Résumé
Cancer immunotherapies (CITs) have revolutionized the treatment of certain cancers, but many patients fail to respond or relapse from current therapies, prompting the need for new CIT agents. CD8 To this end, we discovered and developed a 13-kDa single-domain antibody (VHH5v2) against human CD8 to enable high-quality, same-day imaging with a reduced radiation burden. To enable sensitive and rapid imaging, we employed a site-specific conjugation strategy to introduce an The anti-CD8 VHH, VHH5v2, demonstrated binding to a membrane distal epitope of human CD8 with a binding affinity (K Our work reveals the potential of this anti-human CD8 VHH [
Identifiants
pubmed: 36346438
doi: 10.1007/s00259-022-05998-0
pii: 10.1007/s00259-022-05998-0
doi:
Substances chimiques
Single-Domain Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
679-691Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, et al. Response prediction and evaluation using PET in patients with solid tumors treated with immunotherapy. Cancers. 2021;13:3083.
doi: 10.3390/cancers13123083
Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8
doi: 10.1038/s41416-020-01048-4
Huang Y, Park Y, Wang-Zhu Y, Larange A, Arens R, Bernardo I, et al. Mucosal memory CD8
doi: 10.1038/ni.2106
Moebius U, Kober G, Griscelli AL, Hercend T, Meuer SC. Expression of different CD8 isoforms on distinct human lymphocyte subpopulations. Eur J Immunol. 1991;21:1793–800.
doi: 10.1002/eji.1830210803
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.
doi: 10.1038/nature13954
Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O’Donoghue JA, et al. First-in-humans imaging with
doi: 10.2967/jnumed.119.229781
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, et al. Preclinical development of ZED8 an
Kist de Ruijter L, van de Donk PP, Hooiveld-Noeken JS, Giesen D, Ungewickell A, Fine B, et al. Abstract LB037:
Feo MSD, Pontico M, Frantellizzi V, Corica F, Cristofaro FD, Vincentis GD.
doi: 10.1007/s40336-021-00462-9
Rashidian M, Ploegh H. Nanobodies as noninvasive imaging tools. Immuno-oncology Technol. 2020;7:2–14.
doi: 10.1016/j.iotech.2020.07.001
Schoonooghe S, Laoui D, Ginderachter JAV, Devoogdt N, Lahoutte T, Baetselier PD, et al. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology. 2012;217:1266–72.
doi: 10.1016/j.imbio.2012.07.009
Abdiche YN, Yeung AY, Ni I, Stone D, Miles A, Morishige W, et al. Antibodies targeting closely adjacent or minimally overlapping epitopes can displace one another. Plos one. 2017;12:e0169535.
doi: 10.1371/journal.pone.0169535
Otwinowski Z, Minor W. [20] Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–26.
doi: 10.1016/S0076-6879(97)76066-X
McCoy AJ, Oeffner RD, Wrobel AG, Ojala JRM, Tryggvason K, Lohkamp B, et al. Ab initio solution of macromolecular crystal structures without direct methods. Proc Natl Acad Sci. 2017;114:3637–41.
doi: 10.1073/pnas.1701640114
Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr Sect D Biological Crystallogr. 2004;60:2126–32.
doi: 10.1107/S0907444904019158
Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr Sect D Biological Crystallogr. 2010;66:213–21.
doi: 10.1107/S0907444909052925
Genst ED, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, et al. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc National Acad Sci. 2006;103:4586–91.
doi: 10.1073/pnas.0505379103
Gill H, Seipert R, Carroll VM, Gouasmat A, Yin J, Ogasawara A, et al. The production, quality control, and characterization of ZED8, a CD8-specific
doi: 10.1208/s12248-019-0392-0
Qi J, Leahy RM. Iterative reconstruction techniques in emission computed tomography. Phys Med Biol. 2006;51:R541–78.
doi: 10.1088/0031-9155/51/15/R01
Wang R, Natarajan K, Margulies DH. Structural basis of the CD8αβ/MHC class I interaction: focused recognition orients CD8β to a T cell proximal position. J Immunol. 2009;183:2554–64.
doi: 10.4049/jimmunol.0901276
Sun J, Kavathas PB. Comparison of the roles of CD8 alpha alpha and CD8 alpha beta in interaction with MHC class I. J Immunol Baltim Md. 1950;1997(159):6077–82.
Bostrom J, Lee CV, Haber L, Fuh G. Therapeutic antibodies, methods and protocols. Methods Mol Biol. 2008;525:353–76.
doi: 10.1007/978-1-59745-554-1_19
Schneider TD, Stephens RM. Sequence logos: a new way to display consensus sequences. Nucleic Acids Res. 1990;18:6097–100.
doi: 10.1093/nar/18.20.6097
Barnett D, Storie I, Granger V, Whitby L, Reilly JT, Brough S, et al. Standardization of lymphocyte antibody binding capacity – a multi-centre study. Clin Lab Haematol. 2000;22:89–96.
doi: 10.1046/j.1365-2257.2000.00286.x
Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214:2243–55.
doi: 10.1084/jem.20161950
Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97.
doi: 10.1146/annurev-biochem-063011-092449
Ewert S, Cambillau C, Conrath K, Plückthun A. Biophysical properties of camelid VHH domains compared to those of human VH3 domains. Biochemistry-us. 2002;41:3628–36.
doi: 10.1021/bi011239a
Mitchell LS, Colwell LJ. Comparative analysis of nanobody sequence and structure data. Proteins Struct Funct Bioinform. 2018;86:697–706.
doi: 10.1002/prot.25497
Mitchell LS, Colwell LJ. Analysis of nanobody paratopes reveals greater diversity than classical antibodies. Protein Eng Des Sel. 2018;31:267–75.
doi: 10.1093/protein/gzy017
Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541:321–30.
doi: 10.1038/nature21349
Echarti A, Hecht M, Büttner-Herold M, Haderlein M, Hartmann A, Fietkau R, et al. CD8
doi: 10.3390/cancers11091398
Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 2012;53:953–60.
doi: 10.2967/jnumed.111.101527
Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [
doi: 10.7150/thno.13502
Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isotopes. 2013;76:55–62.
doi: 10.1016/j.apradiso.2012.06.034
Rashidian M, Keliher EJ, Bilate AM, Duarte JN, Wojtkiewicz GR, Jacobsen JT, et al. Noninvasive imaging of immune responses. P Natl Acad Sci Usa. 2015;112:6146–51.
doi: 10.1073/pnas.1502609112
Barakat S, Berksoz M, Zahedimaram P, Piepoli S, Erman B. Nanobodies as molecular imaging probes. Free Radical Bio Med. 2022;182:260–75.
doi: 10.1016/j.freeradbiomed.2022.02.031
Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201–12.
doi: 10.1007/s002590050216
Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77:2318–27.
doi: 10.1158/0008-5472.CAN-16-3346
Roth KS, Voltin C-A, van-Heek L, Wegen S, Schomaecker K, Fischer T, et al (2022) Dual-tracer PET/CT protocol with [
Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59:3–12.
doi: 10.2967/jnumed.116.184028